Profit Warnings & Pricing Pressures

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us today.

SaraAnd I'm Sara. Always good to be here — and I'll say, I've had today's topics circled since this morning. The HCA warning in particular feels like a bellwether moment.

MarcusSame here. We're looking at HCA's profit warning and what it signals for US healthcare access pressures — the system sustainability angle is impossible to ignore. Then we'll break down SubQ Leqembi's approval and its implications for HEOR evidence generation. Next, the FTC settlement with CVS Caremark over insulin pricing — a major enforcement shift. And finally, ICER's expanded scientific advice program and how it's reshaping early evidence strategy.

SaraThat second one on SubQ Leqembi is particularly interesting — the HEOR implications of a new administration route could fundamentally change how we model real-world evidence requirements.

MarcusExactly. Let's get into it.

MarcusStarting with HCA's profit warning. The nation's largest hospital operator cited lower patient volumes and higher uncompensated care costs as drivers. What strikes me here is how this isn't just a financial story — it's a direct signal that the US healthcare system's access pressures are becoming unsustainable at the provider level. We're seeing the downstream effects of reimbursement policy and coverage decisions playing out in real time.

SaraThat's one read — but I'd frame it slightly differently. The part that gives me pause is how this connects to broader systemic fragility. When major hospital systems warn about profitability, it's not just about their bottom line; it's about whether the system can maintain capacity for innovative treatments. The budget impact question here extends beyond drug pricing to entire healthcare infrastructure.

MarcusThat's fair, though I think we should note that HCA specifically mentioned reduced commercial insurance enrollment and higher charity care. It's a classic sign of cost-shifting and underinsurance. What's interesting for our audience is how this might influence payer negotiations — providers under pressure could become more flexible on formulary access in exchange for better reimbursement terms.

SaraI wonder if that's the full picture though. HCA's warning came alongside reports of rising bad debt and charity care costs. The system is absorbing more uncompensated care, which means fewer resources for capital investment and innovation adoption. For market access teams, this creates a paradox: pressure to demonstrate value while the very systems delivering care are becoming financially unstable. The opportunity cost question for payers just got more complex.

MarcusExactly, and what's interesting is how this intersects with the IRA's inflation rebates. Providers are squeezed between payer demands for lower prices and the operational realities of delivering care. The patient perspective here is critical too — when hospitals cut services or delay investments, access to novel treatments suffers. This isn't just a financial metric; it's an access metric.

SaraThe thread I keep coming back to is sustainability. If major hospital systems can't maintain profitability, the entire value proposition for innovative therapies gets called into question. We might see payers becoming even more stringent on cost-effectiveness thresholds, not because they're being difficult, but because the system literally can't afford otherwise. This one caught me off guard — it feels like a tipping point.

MarcusAgreed. Let's shift gears to SubQ Leqembi's approval. The FDA's decision for this subcutaneous formulation of lecanemab represents a significant shift in Alzheimer's treatment administration. For HEOR teams, this isn't just a new delivery route — it's a potential game-changer for real-world evidence generation and cost modeling. The reduction in administration time and complexity could dramatically lower the cost burden of care.

SaraThat's a crucial point. The methodological implications are substantial. With IV administration, you're looking at dedicated infusion centers, nursing time, and facility overhead — all factors that complicate cost-effectiveness analyses. A subcutaneous option could simplify that, but we need to see how real-world adherence and outcomes compare. The payer question here is whether the convenience offsets the drug's price in a way that moves the needle on budget impact.

MarcusRight, and I'd push back slightly on the assumption that convenience automatically equals cost savings. We have to consider the supply chain implications — subcutaneous formulations may require different cold chain logistics, and there's the question of caregiver burden shifting from infusion centers to home administration. What's striking here is how this approval forces HEOR teams to re-evaluate the entire cost equation beyond just the drug's list price.

SaraThat's fair, though I think payers would see it differently. The key variable is likely to be comparative effectiveness against other Alzheimer's therapies. If SubQ Leqembi demonstrates similar efficacy with lower administration costs, that's a compelling value proposition. But if the efficacy profile differs, we're back to the traditional cost-per-QALY calculation. The budget impact question here hinges entirely on how the new formulation fits into the existing treatment paradigm.

MarcusI keep coming back to the evidence generation timeline. With accelerated approvals, we're often operating with limited long-term data. A subcutaneous formulation might change how we design post-marketing studies — potentially larger RWE programs focused on real-world utilization patterns rather than traditional clinical endpoints. The patient perspective matters too: reducing infusion burden could improve quality of life, but we need PRO data to capture that.

SaraAbsolutely. The operationalization of that value is where it gets tricky. How do we quantify the time savings for caregivers and patients in a way that HTA bodies recognize? This is one of those stories where the science is advancing faster than our value assessment frameworks can adapt. We'll need new methodologies to capture these non-traditional benefits.

MarcusMoving to the FTC settlement with CVS Caremark over insulin pricing. The $20 million settlement resolves allegations that the PBM engaged in deceptive practices by switching patients to higher-cost insulin products without proper disclosure. What this signals is a significant enforcement shift toward PBMs' business practices, which have historically been opaque. For market access teams, this could mean greater scrutiny on rebate structures and formulary placement decisions.

SaraThat's one read — I'd frame it slightly differently. The part that gives me pause is how this connects to the broader insulin pricing debate. While the settlement itself is relatively small, the precedent matters. The FTC is essentially saying that PBMs must be transparent about their role in insulin pricing. For payers, this could mean more pressure to pass savings through to patients, but it also highlights how complex the supply chain has become. The budget impact question here extends beyond drug costs to administrative overhead.

MarcusExactly, and what's interesting is how this might influence formulary negotiations. If PBMs face increased regulatory scrutiny, they might become more aggressive in negotiating rebates, which could create tension with manufacturers. The patient perspective is critical here — the settlement specifically mentions patients who faced unexpected costs due to formulary changes. This reinforces the need for value demonstration that goes beyond list price to out-of-pocket costs.

SaraI wonder if that's the full picture though. The settlement doesn't address the fundamental issue of insulin list prices. It's about PBM transparency, not manufacturer pricing. For market access teams, this creates an interesting dynamic: while we're being pushed to demonstrate value, the actual cost drivers remain in different parts of the system. The opportunity cost question for payers becomes even more complicated when they're dealing with multiple layers of pricing complexity.

MarcusThat's fair, though I think we should note that the FTC's action is part of a broader pattern. With the IRA's insulin cap and now this enforcement, there's clear momentum toward greater price transparency across the supply chain. For HEOR teams, this means we need to model total system costs more holistically — including PBM fees and administrative burdens. The evidence requirements are evolving to capture the full value proposition beyond just the drug's efficacy.

SaraThe thread I keep coming back to is trust. When patients face unexpected costs due to formulary changes, it undermines confidence in the entire healthcare system. This settlement is about restoring that trust through transparency. For market access, that means being able to articulate how our products fit into the broader cost structure in a way that payers and patients can understand. It's not just about the science anymore; it's about operational transparency.

MarcusFinally, ICER's expansion of its scientific advice program. The organization is now offering earlier, more structured guidance on evidence generation strategies, particularly for high-cost therapies. What this signals is a recognition that the traditional development pathway often generates evidence too late for meaningful value demonstration. For manufacturers, this represents an opportunity to shape evidence requirements before Phase III trials are even designed.

SaraThat's a crucial point. The methodological implications are substantial. Earlier engagement could help avoid the common pitfall of developing evidence that doesn't align with HTA bodies' needs. But I'm curious about the practical realities — how does ICER balance the needs of innovators with the requirement for rigorous evidence? The budget impact question here is whether earlier guidance actually reduces development costs or just shifts them earlier in the process.

MarcusRight, and I'd push back slightly on the assumption that earlier guidance automatically leads to better outcomes. We've seen cases where early scientific advice creates false confidence, only to face unexpected challenges in Phase III. What's striking here is how ICER's expansion reflects the growing complexity of evidence generation, especially for novel mechanisms where traditional endpoints may not capture full value. The patient perspective matters too — earlier evidence development could mean faster access if it's done right.

SaraThat's fair, though I think payers would see it differently. The key variable is likely to be the timing of evidence generation. If manufacturers can demonstrate value earlier in the process, it could streamline HTA assessments and reduce delays. But there's a risk of confirmation bias if evidence is designed to meet pre-specified criteria. The opportunity cost question for payers is whether this program leads to more efficient resource allocation or just more evidence generation for its own sake.

MarcusI keep coming back to the operational challenges. Implementing earlier scientific advice requires significant coordination between R&D, HEOR, and commercial teams. Many organizations aren't structured to handle that level of early integration. What's interesting is how this could reshape internal HEOR strategies — we might see more dedicated teams focused on pre-Phase III evidence planning. The evidence generation timeline is effectively being compressed.

SaraAbsolutely. The real question is whether this translates to better value demonstration. We've seen cases where early engagement led to more targeted evidence, but also cases where it created unrealistic expectations. For market access teams, this program offers a chance to influence evidence design, but it requires a different kind of strategic thinking — more proactive, more collaborative with HTA bodies. This is one of those stories where the potential is clear, but the execution will determine success.

SaraA lot to think about today. I'll be watching how HCA's profit warning influences payer negotiations on innovative therapies — particularly whether we see more flexible access requirements in exchange for evidence generation commitments.

MarcusSame — and for me the thread running through today is how access pressures are forcing a reevaluation of value demonstration across the entire healthcare system. From provider sustainability to PBM transparency to early evidence generation, the traditional models are being stress-tested.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.